zurück

Zanubrutinib (news indication: chronic lymphocytic leukemia (CLL), first line treatment)

 

Subject:

  • Active Substance: Zanubrutinib
  • Name: Brukinsa®
  • Therapeutic area: Chronic lymphocytic leukemia (CLL)
  • Pharmaceutical company: BeiGene Germany GmbH

 

Time table:

  • Start: 15.12.2022
  • Final decision by G-BA: 15.06.2023

 

Final decision:

  1. Patients without genetic risk factors for whom therapy with FCR is not suitable: Hint of minor additional benefit
  2. Patients with risk factors and patients without risk factors for whom therapy with FCR is suitable: No additional benefit proved